Top

Reactions Weekly

Published in:

01-12-2023 | Rituximab | Case report

Mycophenolate-mofetil/Rituximab

Pneumonia

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Kim S-H, et al. Immunosuppressive therapy in elderly patients with neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal 29 (Suppl.): 146 abstr. P013, No. 3, Oct 2023. Available from: URL: https://doi.org/10.1177/13524585231196192 [abstract]

Title: Mycophenolate-mofetil/Rituximab
Pneumonia
Publication date: 01-12-2023
Publisher: Springer International Publishing
Keywords: Rituximab
Rituximab
Neuromyelitis Optica Spectrum Disease
Pneumonia
Mycophenolate Mofetil
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-52111-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Mycophenolate-mofetil/Rituximab

Pneumonia

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Multiple drugs

Amfetamine

Elasomeran/Tozinameran

Heparin

FDA announces approval of opioid analgesic labelling updates

Hydromorphone/oxycodone